Clinical trial
An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once…
NCT00415142 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00415142 |
|---|---|
| Title | An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder |
| Official title | An Eight-week, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Study, With Escitalopram as an Active Control, to Evaluate the Efficacy, Safety and Tolerability of a Saredutant 100 mg Dose Once Daily, in Elderly Patients With Major Depressive Disorder |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Depressive Disorder |
| Intervention type | Drug |
| Interventions | saredutant (SR48968), placebo, escitalopram |
| Enrollment | 393 |
| Start date | Dec 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Dec 22, 2006 |
| Last update posted | May 24, 2016 |
| Countries | Croatia, Czechia, France, Mexico, Russia, Sweden, Turkey (Türkiye), United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: